Tata Capital’s PE fund raises Rs 955 cr to be invested in pharma, healthcare sectors

Mumbai: Tata Capital on Monday announced a Rs 955 crore fundraise by a private equity arm for investing in healthcare companies. The Tata Capital Healthcare Fund II (TCHF II) achieved a final closure of its fund with investor commitments of Rs 955 crore or USD 126 million, a statement by Tata Capital said.

The offering is a follow-up to the Tata Capital Healthcare Fund I which had raised Rs 411 crore in 2012.

The second fund has garnered commitments from domestic and international financial and strategic institutions including some of the global pharma, medical equipment companies, development financial institutions and large European institutions, it said, adding Government of India has also committed money through the Self Reliant India fund.

TCHF II will principally be taking equity positions in healthcare and life sciences related companies having significant business exposure to India, its managing partner Visalakshi Chandramouli said.

About 60 per cent of the new fund’s bets will be focused on the theme of domestic healthcare and life sciences consumption, while the rest will be devoted to companies focused on healthcare and life sciences competency through delivering products or services to the world markets, Chandramouli elaborated.

The new fund has already committed money to three companies namely Linux Pharma (domestic pharma formulations), Atulaya Healthcare (diagnostic services) and Deeptek Inc (digital health), and expects to announce the fourth investment shortly, its partner Vamesh Chovatia added.

It has a pipeline of deals and is expected to continue the deal momentum in the coming months, Chovatia said, adding, it is typically looking at committing USD 5-15 million per transaction and potentially a larger ticket size along with co-investment support from its limited partners, who have committed to investing in the fund. PTI AA

  • Related Posts

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    New Delhi — India’s top drug regulator has issued a nationwide alert over 90 fixed-dose combination (FDC) drugs being manufactured and sold without mandatory central approval, directing all state and…

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    The Central Drugs Standard Control Organisation (CDSCO), India’s top drug regulator, has identified at least 90 unapproved fixed-dose combination (FDC) medicines in circulation and asked states to move against those…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward